BFM
GALT icon

Boothbay Fund Management’s Galectin Therapeutics GALT Stock Holding History

Boothbay Fund Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-348,200
Closed -$449K – 1542
2024
Q4 		$449K Buy
348,200
+202,000
+138% +$484K 0.01% 919
2024
Q3 		$402K Buy
+146,200
New +$359K 0.01% 1082

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Boothbay Fund Management's GALT Position: Q1 2024 in Review

Boothbay Fund Management sold out of Galectin Therapeutics (GALT) in Q1 2024, closing a stake of 23,749 shares — an estimated $39.4K sold.

Boothbay Fund Management first reported a position in GALT in Q4 2015 and held it in 7 quarters. The position peaked at $105K in Q4 2018. 59 funds tracked by Wall St. Rank hold GALT as of Q1 2024.

  • Boothbay Fund Management reported no remaining Galectin Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Boothbay Fund Management sold 23,749 Galectin Therapeutics shares in Q1 2024, an estimated $39.4K.
  • Boothbay Fund Management first reported a position in Galectin Therapeutics in Q4 2015 and held it in 7 quarters.
  • Boothbay Fund Management's Galectin Therapeutics position peaked at $105K in Q4 2018.
  • 59 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2024.

Based on Boothbay Fund Management's 13F filing for Q1 2024, filed 15 May 2024.